Insights from Biocom’s 2026 Global Life Science Partnering & Investor Conference

Biocom’s 2026 Global Life Science Partnering & Investor Conference held similar themes from last year, continuing to focus on AI in drug discovery, innovation and productivity of drug development in China, perspectives and insights on venture investing, and big pharma partnering and acquisitions.

While the main topics were similar to the 2025 program, the panelists were more divergent in opinions, shared an optimism for innovation, and an interest in more global strategies.

Thus, here are my key takeaways:

Innovation is Welcomed but Clinical Data Remains the Key to Admission

While the hunt for pre-seed or Series A funding was prominent this year in interacting with the various CEOs making their pitch or promoting their innovative ideas, there is a catch 22.

For those in the early development stage, attracting investors now will help catapult your company to the next value inflection point of clinical data. But there is still this notion that there are limited funds and investors are more cautionary and calculated in their outlook.

An investor panel encouraged innovation among the CEOs, encouraging them to continue the dialog early and often, bringing investors along on their journey. However, expect to adapt strategy if the investor feedback received changes the trajectory of their drug development plans. One panelist mentioned knowing when to kill your asset or shift and adapt is critical, even after much blood, sweat, and tears have been poured.

While it is understood investing early on is super risky, what then is the differentiating factor for those early development companies? Still, clinical data remains supreme, and so does a practical, de-risked development roadmap. This ‘show me’ the data and maybe we can get to contract terms was certainly a theme, but development comes at a high cost and not everyone makes it.

Still, in meeting with several CEOs, I found their excitement for their innovative products infectious and interesting – a match with our Halloran services (a PLG company) where we provide regulatory, clinical, and quality assurance support for early-stage companies looking to expand in the U.S., come to the U.S., or explore additional geographics to expand their product development while de-risking their approach.

Global Drug Development Expansion as a Rising Alternative

Throughout conversations at the conference, China is becoming more of a contender in the drug development space due to the cost efficiencies and rapid speed to get to the clinic and obtain clinical data. While last year this concept was more of an introduction, this year there was more evidence of proof as drug development in this country is a rising contender.

In fact, I sat next to someone who asked if we knew people that could help with drug development in China since Halloran recently added global services to include the EU, Australia, and APAC regions.

Additionally, the idea of the international consortium of companies who have assets and want to get their product to the U.S. to raise capital is encouraging for the life sciences ecosystem since it is still a place of attraction despite the changing regulatory landscape. One question stood out to me, “what can I do to capitalize on enter the U.S. market especially if I have preclinical data in another country or Phase 1 clinical data in another country?”

While there is still the desire to have interactions with the U.S. to get through an INTERACT, Pre-IND, and IND submission to start a clinical trial, companies are thinking of alternative global options to start or expand their clinical trial strategies.

Therapeutic Area and Modality Agnostic: Diversify or Complement the Pipelines for Investors

Each year it is interesting to see which way the pendulum swings for venture capitalists and big pharma as they expand their portfolios by adding assets to their current pipelines. The question of trends for 2026 is always of interest for new companies and inquiring minds alike.

Indication wise, oncology continues to be of interest as well as metabolic disease, neurology, and rare disease. Having experience in these four areas, it is interesting to see how oncology, metabolic disease, neurology, and rare disease are growing and continue to acquire approvals and interest from investors.

The modalities were also a topic of discussion since the debate is still live – are small molecules still of interest to investors versus cell and gene therapies? There were differing thoughts on this, but the bottom line was that from a cost perspective, small molecules are cheaper while cell and gene therapies are more expensive from a cost of goods perspective. Thus, manufacturing is a consideration when companies are developing their drug products.

Therefore, Investors (venture capitalists and big pharma) appear to be therapeutic area and modality agnostic but tend to focus on what would be additive or complementary to their pipelines or to help diversify their pipelines depending on their targets of interest.

CEO Leadership & Productive Pitches to Gain, Keep and Secure Interest

Due to weather and travel, some of the panelists could not make the trek to San Diego, and a whole new panel emerged and was pulled together overnight to discuss pharma partnering and acquisitions. Not a small endeavor.

This panel provided some practical tips on what they are looking for in rising CEOs and their companies.

A summary of their feedback:

• Clear value proposition: are they differentiated and is it meaningful for patients?
• Clear understanding of the Target Product Profile, competitive landscape, clinical development plan, regulatory roadmap, and next data/value inflection point
• Have current internal champions that have conviction and tenacity. These are effective leaders with high-functioning teams (You can have great science, but a poor team presents challenges)
• Positive CEO behavior: ability to listen instead of being hostile and resistant
• Know their investor audience and effectively prepare in advance

While all these points are important, there was a follow-on panel on lessons to be learned in venture investing. In this session, there was a continued emphasis on capital and operational efficiency. For capital efficiency, investors want to ensure companies are using their money wisely to warrant focus on execution and cut back on the ‘nice to haves’ to deliver value. From the operational efficiency perspective, investors want to understand the logic chain with storytelling – do the dots connect, and is there an understanding and ability to validate those value inflection points?

Overall, it was interesting to hear the perspectives, gain additional insights, and make connections. Thank you, Biocom, for hosting an engaging conference with intriguing panels all sharing diverse perspectives in such a welcoming environment.